



9-21-05

Zhu
Al-
8

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/057,646	
	Filing Date	January 25, 2002	
	First Named Inventor	Harry R. Davis et al.	
	Art Unit	1617	
	Examiner Name	Shengjun Wang	
Total Number of Pages in This Submission	22	Attorney Docket Number	CV01379K - 4686-045566

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input checked="" type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts Under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	The Webb Law Firm		
Signature			
Printed Name	Ann M. Cannoni		
Date	September 20, 2005	Reg. No.	35,972

CERTIFICATE OF TRANSMISSION / MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as Express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Chris Craig	Date	September 20, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 1633) <h2 style="margin: 0;">FEE TRANSMITTAL</h2> <h3 style="margin: 0;">For FY 2005</h3>		Complete if Known	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Application Number	10/057,646
		Filing Date	January 25, 2002
		First Named Inventor	Harry R. Davis, et al.
		Examiner Name	Shengjun Wang
		Art Unit	1617
TOTAL AMOUNT OF PAYMENT		(\$)	500.00
		Attorney Docket No.	CV01379K/4686-045566

METHOD OF PAYMENT (check all that apply)

☒ Check
 ☐ Credit Card
 ☐ Money Order
 ☐ None
 ☐ Other (please identify): _____

☐ Deposit Account
 Deposit Account Number: 23-0650
 Deposit Account Name The Webb Law Firm

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below
 ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) Under 37 CFR 1.16 and 1.17
 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity		Small Entity		Small Entity		
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	
				Fee (\$)	Fee Paid (\$)
- 20 or HP = _____	x _____	= _____			
HP = highest number of total claims paid for, if greater than 20					

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)		
- 3 or HP = _____	x _____	= _____			
HP = highest number of independent claims paid for, if greater than 3					

3. APPLICATION SIZE FEE


If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Appeal Brief500.00**SUBMITTED BY**

Signature		Registration No. (Attorney/Agent)	35,972	Telephone	412-471-8815
Name (Print/Type)	Ann M. Cannoni		Date	September 20, 2005	

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Response Under 37 C.F.R. §1.192
Appellant's Brief

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**


In re: Patent Application of	:	PATENT APPLICATION
Harry R. Davis et al.	:	
Serial No.: 10/057,646	:	Group Art Unit: 1617
Filed: January 25, 2002	:	Examiner: Shengjun Wang
For: Combinations of Nicotinic Acid and	:	Atty. Docket No.: CV01379K
Derivatives Thereof and Sterol	:	
Absorption Inhibitor(s) and	:	
<u>Treatments for Vascular Indications</u>	:	

MAIL STOP APPEAL BRIEF – PATENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**ON APPEAL FROM THE PRIMARY EXAMINER TO THE
BOARD OF PATENT APPEALS AND INTERFERENCES**

APPELLANT'S BRIEF UNDER 37 C.F.R. § 1.192

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
September 20, 2005	
Date	Signature
Chris Craig	
Typed Name of Person Signing Certificate	

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K





TABLE OF CONTENTS

	Page
TABLE OF CONTENTS.....	I
REAL PARTY IN INTEREST.....	1
RELATED APPEALS AND INTERFERENCES.....	1
STATUS OF CLAIMS.....	1
STATUS OF AMENDMENTS.....	1
SUMMARY OF CLAIMED SUBJECT MATTER.....	2
GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL:	
I. Has a <u>Prima Facie</u> Case of Obviousness Under 35 U.S.C. § 103 Over Claims 1-4, 7-10, 28-30 and 32 as Obvious Over U.S. Patent No. 5,846,966 ("Rosenblum et al.") in view of U.S. Patent No. 5,698,527 ("Kim") and WO 2000/38725 ("Keller et al."). Been Established?.....	4
ARGUMENT.....	4
I. The Required <u>Prima Facie</u> Case of Obviousness of Claims 1-4, 7-10, 28-30 and 32 Under 35 U.S.C. § 103 Over U.S. Patent No. 5,846,966 ("Rosenblum et al.") in view of U.S. Patent No. 5,698,527 ("Kim") and WO 2000/38725 ("Keller et al.").has Failed to be Established.....	4
A. The Rejection.....	4
B. The Prior Art.....	5
C. Discussion.....	6
CLAIMS APPENDIX.....	12
EVIDENCE APPENDIX.....	15
RELATED PROCEEDINGS APPENDIX.....	16

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K



I

REAL PARTY IN INTEREST

The real party in interest in this Appeal is assignee Schering Corporation, having a principal place of business 2000 Galloping Hill Road, Kenilworth, NJ 07033.

II

RELATED APPEALS AND INTERFERENCES

As the legal representative of Appellant, the undersigned attorney has no knowledge of any appeals or interferences directly related to this Appeal.

III

STATUS OF CLAIMS

This is an original patent application in which claims 1-4, 7-10, 28-30 and 32 are pending in the application. Claims 11-27, 36-39, 41, 44-46, 51, 54, 56, 59, 61, 64, 66, 69, 72, 75, 78 and 81 have been withdrawn from consideration by the Examiner as being non-elected. Claims 5, 6, 31 and 33-81 were previously canceled without prejudice to filing one or more divisional applications directed to the subject matter thereof.

Claims 1-4, 7-10, 28-30 and 32 (pending) were finally rejected under 35 U.S.C. §103(a) in an Office Action mailed March 24, 2005 ("Final Office Action") and Advisory Action mailed June 15, 2005 ("Advisory Action").

Twelve (12) pending claims (1-4, 7-10, 28-30 and 32) are at issue in this Appeal.

IV

STATUS OF AMENDMENTS


No claims were amended after final rejection. A copy of the claims involved in this Appeal is contained in the Appendix attached hereto.

V

SUMMARY OF CLAIMED SUBJECT MATTER

In embodiments set forth in claim 1, Applicants have discovered compositions comprising:

- (a) at least one of nicotinic acid or derivatives thereof; and
- (b) 10 milligrams of a sterol absorption inhibitor represented by Formula (II):



or a pharmaceutically acceptable salt or solvate thereof.

See original claims 1 and 5, and page 80 of the specification.

In other embodiments set forth in Claim 32, Applicants have discovered therapeutic combinations comprising:

- (a) a first amount of at least one of nicotinic acid or derivatives thereof; and
- (b) a second amount of 10 milligrams of a compound represented by Formula (II) or pharmaceutically acceptable salt or solvate thereof, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.

The compound of Formula (II) above is ezetimibe, which is the active ingredient in ZETIA™ (ezetimibe) pharmaceutical formulation and VYTORIN™ (ezetimibe/simvastatin) pharmaceutical formulation, both of which are

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

commercially available from MSP (Merck Schering-Plough) Pharmaceuticals, Inc. See Response to Restriction Requirement and Election of Species of ("Restriction and Election Response") at page 2, lines 8-9.

Applicants provisionally elected with traverse nicotinic acid as the species of nicotinic acid or derivatives thereof for initial examination in the application. See Restriction and Election Response at page 2, lines 6-7.

The claimed compositions and combinations can be useful for treating or preventing a vascular condition, diabetes, obesity and/or lowering concentration of a sterol or 5 α -stanol in plasma in a subject. See page 81, lines 1-11 of the specification.

VI

GROUND OF REJECTION TO BE REVIEWED ON APPEAL

- I. Has a Prima Facie Case of Obviousness Under 35 U.S.C. § 103 Over Claims 1-3, 5-28, 31-36, 70-72, 74-77, 79 and 80 as obvious over U.S. Patent No. 5,846,966 ("Rosenblum et al.") in view of U.S. Patent No. 5,698,527 ("Kim") and WO 2000/38725 ("Keller et al.") Been Established?

VII

ARGUMENT

- I. The Required Prima Facie Case of Obviousness of Claims 1-3, 5-28, 31-36, 70-72, 74-77, 79 and 80 Under 35 U.S.C. § 103 Over U.S. Patent No. 5,846,966 ("Rosenblum et al.") in view of U.S. Patent No. 5,698,527 ("Kim") and WO 2000/38725 ("Keller et al.") has Failed to be Established.

- A. The Rejection

Claims 1-4, 7-10, 28-30 and 32 have been rejected as obvious over U.S. Patent No. 5,846,966 ("Rosenblum et al.") in view of U.S. Patent No. 5,698,527 ("Kim") and WO 2000/38725 ("Keller et al.").

The reasons for rejection are set forth in the Final Office Action, summarized as follows:

It is asserted that Rosenblum et al. teach the instant cholesterol absorption inhibitors, their application for lowering serum cholesterol and combination with other cholesterol lowering agents such as simvastatin. Final Office Action at page 2. Further, it is asserted that Rosenblum et al, teach a daily dosage in a range of 5 mg to 1000 mg a dose given 1 or two times a day

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

and that the exact dose would depend upon various conditions. Final Office Action at page 2.

It is acknowledged that Rosenblum et al. do not expressly teach a combination of a cholesterol absorption inhibitor, such as ezetimibe, and a nicotinic acid. Final Office Action at page 3.

In the rejection, it is alleged that Kim teaches that niacin is a well-known cholesterol lowering agent and is particularly useful in combination with cholesterol absorption inhibitors. Final Office Action at page 3. It is further alleged that Keller et al. teach various combinations of cholesterol lowering agents, including ezetimibe and nicotinic acid, for treating hypercholesterolemia-associated disorders. Final Office Action at page 3.

It is alleged that it would have been obvious to one of ordinary skill in the art, at the time that the claimed invention was made, to make a composition comprising ezetimibe and nicotinic acid, and optionally simvastatin, citing In re Kerkoven, 205 U.S.P.Q. 1069. Final Office Action at page 3.

It is further alleged that the specific amount of 10 mg is within the range disclosed by Rosenblum et al. Final Office Action at page 3.

B. The Prior Art

Rosenblum et al. disclose cholesterol absorption inhibitors, their application for lowering serum cholesterol and combination with simvastatin. Rosenblum et al. do not teach a combination of a cholesterol absorption inhibitor, such as ezetimibe, and nicotinic acid, or in further combination with a cholesterol biosynthesis inhibitor, e.g. simvastatin.

Kim discloses steroidal glycoside cholesterol absorption inhibitors that can be administered in combination with niacin, but does not suggest or disclose combining ezetimibe with niacin or the desirability of the claimed amount of 10 milligrams of ezetimibe. Ezetimibe is not a steroidal glycoside.

Keller et al. disclose combinations of (1) an ileal bile acid transport

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

inhibitor or CETP inhibitor and (2) a cholesterol absorption inhibitor such as ezetimibe, but not the combination of ezetimibe and nicotinic acid.

C. The Required Prima Facie Case of Obviousness Under
35 U.S.C. § 103 Has Not Been Established

The law is replete with cases holding that there must be some suggestion or motivation in the prior art to combine the references. When making a rejection under 35 U.S.C. § 103, the Examiner has the burden of establishing a prima facie case of obviousness. In re Fritch, 23 U.S.P.Q.2d 1780, 1783 (Fed. Cir. 1992).

The Examiner can satisfy this burden only by showing an objective teaching in the prior art, or knowledge generally available to one of ordinary skill in the art, which would lead an individual to combine the relevant teachings of the references [and/or the knowledge] in the manner suggested by the Examiner. Id.; In re Fine, 5 U.S.P.Q.2d 1596, 1598 (Fed. Cir. 1988).

The mere fact that the prior art could be modified does not make the modification obvious *unless the prior art suggests the desirability of the modification* (emphasis added). In re Fritch, 23 U.S.P.Q.2d at 1784; In re Laskowski, 10 U.S.P.Q.2d 1397, 1398 (Fed. Cir. 1989); In re Gordon, 221 U.S.P.Q. 1125, 1127 (Fed. Cir. 1984).

"The ultimate determination of patentability must be based on consideration of the entire record, by a preponderance of evidence, with due consideration to the persuasiveness of any arguments and any secondary evidence." Manual of Patent Examining Procedure, (Rev. 1, Feb. 2003) § 716.01(d) and In re Oetiker, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992).

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

Claims 1-4, 7-10, 28-30 and 32

Claims 1 and 32 recite a composition and therapeutic combination, respectively, comprising: (a) at least one nicotinic acid or derivative thereof; and (b) about 10 milligrams of at least one sterol absorption inhibitor represented by Formula (II) above.

Claim 2 depends from claim 1 and further recites that the at least one of nicotinic acid or derivatives thereof is selected from the group consisting of nicotinic acid, niceritrol, nicofuranose, acipimox and mixtures thereof.

Claim 3 depends from claim 2 and further recites that the at least one of nicotinic acid or derivatives thereof is nicotinic acid.

Claim 4 depends from claim 1 and further recites that the at least one of nicotinic acid or derivatives thereof is administered to a mammal in an amount ranging from about 500 to about 10,000 milligrams of nicotinic acid or derivatives thereof per day.

Claim 7 depends from claim 1 and further recites that the composition further comprises at least one cholesterol biosynthesis inhibitor.

Claim 8 depends from claim 7 and further recites that the at least one cholesterol biosynthesis inhibitor comprises at least one HMG CoA reductase inhibitor.

Claim 9 depends from claim 8 and further recites that the at least one HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, cerivastatin and mixtures thereof.

Claim 10 depends from claim 9 and further recites that the at least one HMG CoA reductase inhibitor is simvastatin.

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

Claim 28 depends from claim 1 and recites a pharmaceutical composition for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier.

Claim 29 depends from claim 1 and recites a method of treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment an effective amount of the composition of claim 1.

Claim 30 depends from claim 29 and further recites that the vascular condition is hyperlipidemia.

As shown in Table 1 of the present application, Compound XII (a substituted azetidinone cholesterol absorption inhibitor) reduced plasma cholesterol levels and the accumulation of hepatic cholesteryl esters in the cholesterol-fed hamsters. Niacin reduced plasma triglyceride levels, but did not significantly reduce the cholesterol levels. The combination of Compound XII and niacin resulted in reductions in plasma and hepatic cholesterol levels, as well as plasma triglycerides (Table 1). These results indicate that the combination of the cholesterol absorption inhibitor of Compound XII and niacin can have additive effects on treating hyperlipidemia in male Golden Syrian hamsters, by reducing both cholesterol and triglyceride levels. One skilled in the art would understand that the compatibility and efficacy of drug combinations can be unpredictable.

Rosenblum et al. do not suggest or disclose the combination of ezetimibe and nicotinic acid. Rosenblum et al. do not suggest or disclose the

desirability of a 10 milligram dosage of ezetimibe. Rosenblum et al. do not suggest or disclose lowering of triglyceride levels.

Kim discloses steroidal glycoside cholesterol absorption inhibitors that can be administered in combination with niacin, but does not suggest or disclose combining ezetimibe with niacin or the desirability of the claimed amount of 10 milligrams of ezetimibe. Ezetimibe is not a steroidal glycoside. The steroidal glycosides disclosed by Kim are structurally very dissimilar to the presently claimed substituted azetidinone compound ezetimibe. Given their large molecular size, it is unlikely that Kim's steroidal glycosides are absorbed through the intestine. In contrast, multiple peaks in plasma concentration-time profiles suggest that the glucuronide conjugate of ezetimibe undergoes enterohepatic recycling before elimination. See ZETIA™ (ezetimibe) Tablets Package Insert at column 2 (Merck/Schering-Plough Pharmaceuticals) (October 2002), included in the Information Disclosure Statement of August 30, 2004. This enterohepatic recycling can enhance efficacy. It would not be obvious to one of ordinary skill in the art to substitute ezetimibe disclosed by Rosenblum et al. for the steroidal glycosides disclosed by Kim, since they are likely to be dissimilar in site of action.

Kim's steroidal glycoside compounds have not been commercialized by Merck & Co., Inc. (the assignee of the Kim patent). Rather, Merck is the joint venture partner of Schering-Plough (assignee of the present application) in marketing the cholesterol absorption inhibitor ZETIA™ ezetimibe formulation. ZETIA was launched in late 2002 and global sales of ZETIA in the 2003 fourth

quarter totaled \$165 million, with U.S. sales of \$144 million. Press Release: Schering-Plough Reports Financial Results for 2003 Fourth Quarter, Full Year (Monday January 26, 6:33 am ET). Thus it can be inferred that Kim's steroidal glycoside compounds, administered alone or in combination with niacin, were not commercially viable as treatments.

"[S]econdary considerations such as ... commercial success, long-felt need, failure of others ... are relevant to the issue of obviousness and must be considered in every case in which they are present. When evidence of any of these secondary considerations is submitted, the examiner must evaluate the evidence." M.P.E.P. § 2141 (Rev'd May 2004). Applicants respectfully request that the above information regarding commercial success, long-felt need, and failure of others be considered by the Examiner.

No data is presented in the Kim reference to support efficacy of a combination of steroidal glycoside and niacin. One skilled in the art would not be motivated to combine ezetimibe and nicotinic acid based upon the disclosure of Kim since the steroidal glycoside and ezetimibe molecules are so structurally dissimilar.

Keller et al. disclose combinations of (1) an ileal bile acid transport inhibitor or CETP inhibitor and (2) a cholesterol absorption inhibitor such as ezetimibe, but *not the combination of ezetimibe and nicotinic acid*. Also, Keller does not suggest or disclose the desirability of a 10 mg dosage of ezetimibe.

It is respectfully submitted that the combination of the references cited as rendering the claimed invention obvious is improper because there is no

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

suggestion in any of the cited references, taken alone or combined as advocated in the rejection, to combine the claimed components of 10 milligrams of ezetimibe and nicotinic acid.

Even if the teachings of the references were combined as set forth in the Office Action, there are not sufficient teachings to motivate one of ordinary skill in the art to pick and choose among thousands of compounds to combine 10 milligrams of ezetimibe with nicotinic acid.

Neither Rosenblum et al, Kim, nor Keller et al., taken alone or combined as set forth in the Office Action, provides motivation for combining 10 milligrams of ezetimibe and niacin. Also, Applicants respectfully request that the above information regarding commercial success, long-felt need, failure of others be considered by the Examiner.

Applicants respectfully assert that the rejection is based upon improper hindsight reconstruction. The prima facie case of obviousness has not been established. Accordingly, Applicants respectfully request that the § 103(a) rejection of claims 1-4, 7-10, 28-30 and 32 be reconsidered and withdrawn.

Respectfully submitted,


Date: September 20, 2005



Ann Marie Cannoni
Registration No. 35,972
The Webb Law Firm, P.C.
700 Koppers Building
Pittsburgh, PA 15219
Phone: (412) 471-8815
Fax: (412) 471-4094
E-mail: acannoni@webblaw.com

CLAIM APPENDIX

1. A composition comprising:
 - (a) at least one of nicotinic acid or derivatives thereof; and
 - (b) 10 milligrams of a sterol absorption inhibitor represented by Formula (II):



or a pharmaceutically acceptable salt or solvate thereof.

2. The composition according to claim 1, wherein the at least one of nicotinic acid or derivatives thereof is selected from the group consisting of nicotinic acid, niceritrol, nicofuranose, acipimox and mixtures thereof.
3. The composition according to claim 2, wherein the at least one of nicotinic acid or derivatives thereof is nicotinic acid.
4. The composition according to claim 1, wherein the at least one of nicotinic acid or derivatives thereof is administered to a mammal in an amount ranging from about 500 to about 10,000 milligrams of nicotinic acid or derivatives thereof per day.
7. The composition according to claim 1, further comprising at least one cholesterol biosynthesis inhibitor.

8. The composition according to claim 7, wherein the at least one cholesterol biosynthesis inhibitor comprises at least one HMG CoA reductase inhibitor.

9. The composition according to claim 8, wherein the at least one HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, cerivastatin and mixtures thereof.

10. The composition according to claim 9, wherein the at least one HMG CoA reductase inhibitor is simvastatin.


28. A pharmaceutical composition for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier.

29. A method of treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment an effective amount of the composition of claim 1.

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

30. The method according to claim 29, wherein the vascular condition is hyperlipidemia.

32. A therapeutic combination comprising: (a) a first amount of at least one of nicotinic acid or derivatives thereof; and (b) a second amount of 10 milligrams of a compound represented by Formula (II) below:



(II)

or pharmaceutically acceptable salt or solvate thereof, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.

Response Under 37 C.F.R. §1.192
Appellant's Brief

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

EVIDENCE APPENDIX

None.

Response Under 37 C.F.R. §1.192
Appellant's Brief

Application No. 10/057,646
Paper Dated: September 20, 2005
Attorney Docket No. CV01379K

RELATED PROCEEDINGS APPENDIX

None.